What's Happening?
Glaukos Corporation has announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent J-code for Epioxa, a treatment for keratoconus. The new J-code, J2789, will become effective on July 1, 2026, facilitating streamlined
billing and reimbursement for the treatment. Epioxa offers an incision-free alternative to traditional corneal cross-linking procedures, providing a less painful and more efficient treatment option for patients. This development is expected to improve market access and expand coverage for patients suffering from this rare eye disease.
Why It's Important?
The assignment of a permanent J-code for Epioxa represents a significant advancement in the treatment of keratoconus, a condition that can lead to severe vision impairment if left untreated. By simplifying the billing process, the new J-code is likely to enhance patient access to this innovative treatment, potentially improving outcomes for those affected by the disease. For Glaukos, this milestone supports its market access initiatives and strengthens its position in the ophthalmic pharmaceutical industry. The development also underscores the importance of regulatory support in facilitating the adoption of novel medical technologies.
